Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

REDWOOD CITY, Calif., Dec. 9 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery. The primary endpoint evaluated pain intensity (Sum of the Pain Intensity Difference - SPID12) over the 12-hour study period compared to baseline. Results demonstrated that compared to placebo, patients receiving 15 mcg of ARX-01 experienced a statistically significant reduction in pain intensity over the study period, based on the worst observation carried forward imputation method (WOCF), p=0.015. Additionally, at the 15 mcg dose, the study met an important secondary endpoint compared to placebo, the percentage of patient dropouts due to inadequate analgesia, p=0.006. Further, no serious or unexpected adverse events related to ARX-01 were reported in the study.

ARX-01 is a sublingual formulation of the opioid pain medication, sufentanil. ARX-01 is based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

"We chose a very painful surgery in an elderly patient population to showcase the efficacy and safety of Sublingual Sufentanil NanoTabs in treating acute post-operative pain," said Pamela Palmer, M.D., Ph.D., chief medical officer of AcelRx Pharmaceuticals. "The superior attributes of both the drug and the dosage form enabled these highly encouraging Phase 2 results."

This multicenter, double-blind, randomized, placebo-controlled, dose-finding Phase 2 study evaluated the safety and efficacy of ARX-01 in patients undergoing elective unilateral knee replacement surgery. In the study, 101 patients were randomized to receive either placebo or one of three different dosage strengths of ARX-01: 5mcg, 10m
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Texas , May 29, 2015  Caris ... from two studies in which researchers utilized Caris ... service, to identify potential therapeutic targets in patients ... expression of the programmed cell death protein 1 ... on June 1 at the 2015 American Society ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... IN (PRWEB) May 28, 2015 The Academy ... National Model Aviation Day on August 15, 2015. National Model ... aviation nation-wide and to introduce model flying to the general ... 2,350 chartered clubs to participate in the celebration by hosting ... registered to host National Model Aviation Day events. View ...
Breaking Biology Technology:Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2
... Palatin,Technologies, Inc. (Amex: PTN ) announced today ... PL-3994, a novel, long-acting natriuretic peptide,receptor A (NPRA) ... heart failure (CHF). The Phase I trial was ... 26 healthy volunteers who received the medication or ...
... AutoGenomics, a leader in,developing automated molecular testing solutions, ... healthcare and biotechnology companies presenting,at the 28th Annual ... at the,Boston Marriott Copley Place in Boston, Massachusetts. ... an overview of the,company, its automated molecular testing ...
... Protection Agency (EPA) to fine California technology company IOGEAR ... applauded by David Rejeski, the director of the Project ... big pat on the back for making this effort, ... that has been on the books for decades can ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... provides nearly half the daily calories for the world,s population ... events by colonizing its seeds or plants with the spores ... shows. In an effort to explore ways to ... tsunamis and tidal surges that have already led to rice ...
... This release is available in German . ... Germany, has made a significant contribution towards the exploration of ... NASA. The Mainz research team led by Dr Gstar Klingelhfer ... cooperating with JAXA, the Japanese space agency. It is planned ...
... A custom-built, $2.5 million "split magnet" system with the ... has made its debut at the National High Magnetic Field ... operating at 25 tesla, easily besting the 17.5 tesla French ... named for early 20th-century inventor and engineer Nikola Tesla, is ...
Cached Biology News:Climate adaptation of rice 2Climate adaptation of rice 3Moessbauer group of Mainz University preparing for participation in Japanese moon mission 2Moessbauer group of Mainz University preparing for participation in Japanese moon mission 325 Tesla, world-record 'split magnet' makes its debut 225 Tesla, world-record 'split magnet' makes its debut 3
...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
... a 10.0 kb Autographa californica (AcNPV) polyhedrin ... AcNPV polyhedrin promoter and two AcNPV p10 ... a Sma I cloning site, followed by ... inverted polyhedrin promoter has been inserted containing ...
Biology Products: